Citigroup has initiated coverage on Rhythm Pharmaceuticals Inc (RYTM) with a Buy rating, reflecting the firm's assessment of the company's potential in the biotechnology sector. This marks Citigroup's first evaluation of Rhythm, which specializes in developing therapeutics for rare diseases, particularly focusing on its melanocortin-4 receptor (MC4R) agonists.
Headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals is known for its lead asset, IMCIVREE, a precision medicine approved by the Food and Drug Administration (FDA) for chronic weight management in patients with specific genetic obesity disorders. The company currently employs 283 full-time staff and has a market capitalization of $7.2 billion.
As of November 24, 2025, Rhythm Pharmaceuticals' stock is priced at $107.42. The upcoming earnings reports are anticipated on May 5, 2026, with an estimated EPS of -$0.86 and revenue of $58.9 million. Analysts have noted a consensus rating of Buy, with 8 Strong Buy, 11 Buy, and 1 Hold ratings as of November 1, 2025.
While analyst ratings provide insights based on research and financial models, they should be considered alongside various factors, including company fundamentals and market trends. Analyst opinions can evolve as new information emerges, and it is essential for investors to evaluate multiple inputs in their decision-making process.